Carisma Therapeutics (CARM) Projected to Post Quarterly Earnings on Monday

Carisma Therapeutics (NASDAQ:CARM) will likely be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $5.42 million for the quarter.

Carisma Therapeutics Trading Down 0.3 %

CARM stock opened at $0.19 on Friday. The firm has a fifty day moving average price of $0.42 and a 200 day moving average price of $0.64. Carisma Therapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $2.05. The firm has a market cap of $8.01 million, a PE ratio of -0.12 and a beta of 1.56. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23.

Analysts Set New Price Targets

A number of equities analysts have commented on CARM shares. BTIG Research cut shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Baird R W lowered Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. Evercore ISI reissued an “in-line” rating and set a $0.70 target price (down previously from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. Finally, D. Boral Capital decreased their price target on Carisma Therapeutics from $12.00 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Carisma Therapeutics currently has a consensus rating of “Hold” and an average price target of $2.74.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.